2019
Impact of Age and Life-expectancy on Treatment Receipt in High-risk Prostate Cancer
Fei K, Lin J, Supoyo S, Franco R, Abramson S, Hoke G, Oh W, Stock R, Bickell N. Impact of Age and Life-expectancy on Treatment Receipt in High-risk Prostate Cancer. Journal Of Advances In Medicine And Medical Research 2019, 1-9. DOI: 10.9734/jammr/2019/v30i1130248.Peer-Reviewed Original ResearchHigh-risk prostate cancer patientsHigh-risk prostate cancerProstate cancer patientsProstate cancerTreatment decision-makingTreatment of high-risk prostate cancerHigh-risk localized prostate cancerCancer patientsClinically Significant Prostate CancerIncidence of prostate cancerImpact treatment decision-makingAndrogen deprivation therapySignificant prostate cancerLocalized prostate cancerOlder menAssociated with lower ratesMedical conditionsLife expectancyTreatment receiptPatient's life expectancyType of treatmentSurgical receiptDeprivation therapyRadical prostatectomyDefinitive therapy
2016
Emerging Technologies and Techniques in Radiation Therapy
Magnuson W, Mahal A, Yu J. Emerging Technologies and Techniques in Radiation Therapy. Seminars In Radiation Oncology 2016, 27: 34-42. PMID: 27986210, DOI: 10.1016/j.semradonc.2016.08.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyHigh-dose-rateProton beam radiationRadiation therapyProstate cancerHigh-dose-rate (HDR) brachytherapyHigh-risk prostate cancer patientsHigh-risk prostate cancerTreatment of prostate cancerPartial gland treatmentProstate-directed therapyRegional radiation therapyLow-risk diseaseBeam radiationProstate cancer patientsDeliver radiationImprove cancer controlHigh-Intensity Focused UltrasoundFocal therapyTherapeutic modalitiesRadiation treatmentCancer patientsCancer controlTherapyReduced toxicity
2015
Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy
Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR. Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2015, 91: 832-839. PMID: 25752398, DOI: 10.1016/j.ijrobp.2014.11.035.Peer-Reviewed Original ResearchMeSH KeywordsAnatomic LandmarksCone-Beam Computed TomographyFiducial MarkersHumansLymph NodesLymphatic IrradiationMaleMovementOrgan SizePelvic BonesPelvisProstateProstatic NeoplasmsRadiosurgeryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiotherapy, Image-GuidedRectumSeminal VesiclesUrinary BladderConceptsNodal coverageCone-beam CTKilovoltage cone-beam CTHigh-risk prostate cancer patientsHigh-risk prostate cancerNodal clinical target volumeStereotactic body radiation therapyBladder-filling protocolPelvic lymph nodesMajority of patientsSubset of patientsRadiation therapy regimenProstate cancer patientsBody radiation therapyClinical target volumeAverage V100Multimodality bladderSBRT regimenStrict bladderLymph nodesPelvic nodalTherapy regimenCancer patientsProstate cancerRadiation therapy
2010
Neoadjuvant and Adjuvant Therapies in Prostate Cancer
Schutz F, Oh W. Neoadjuvant and Adjuvant Therapies in Prostate Cancer. Urologic Clinics Of North America 2010, 37: 97-104. PMID: 20152523, DOI: 10.1016/j.ucl.2009.11.012.Peer-Reviewed Original ResearchConceptsRisk of recurrenceAdjuvant therapyProstate cancerHigh-risk prostate cancer patientsProstate cancer-specific deathHigh risk of recurrenceSystemic adjuvant therapyCancer-specific deathProstate cancer patientsPostoperative radiotherapyMetastatic diseaseRadiation therapyHormone therapySurgical therapyClinical criteriaCancer patientsCancer deathProstateTherapyHigh riskCancerChemotherapyRecurrencePatientsDeath
2005
A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaula R, Beer T, Eisenberger M. A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal Of Clinical Oncology 2005, 23: 4565-4565. DOI: 10.1200/jco.2005.23.16_suppl.4565.Peer-Reviewed Original Research
2004
Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.14_suppl.4649.Peer-Reviewed Original ResearchAdjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.90140.4649.Peer-Reviewed Original Research
2002
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer
D'Amico A, Saegaert T, Chen M, Renshaw A, George D, Oh W, Kantoff P. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer. Cancer 2002, 95: 275-280. PMID: 12124826, DOI: 10.1002/cncr.10673.Peer-Reviewed Original ResearchConceptsAndrogen suppression therapyProstate specific antigen failureProstate specific antigenProstate cancer patientsHigh-risk prostate cancer patientsMonths of androgen suppression therapyNeoadjuvant androgen suppression therapyRadiation therapyHgb levelsCancer patientsPSA failureHormone therapyRelative risk of PSA failureTreatment of prostate cancer patientsEstimates of PSA outcomeHigh-risk prostate cancerMultivariate analysisRisk of PSA failureExternal beam radiation therapyThree-dimensional conformal RTCox regression multivariate analysisBaseline PSA levelsEarly PSA failureNeoadjuvant hormonal therapyBeam radiation therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply